Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease.

Kirstein J, Hoffmann A, Lilie H, Schmidt R, Rübsamen-Waigmann H, Brötz-Oesterhelt H, Mogk A, Turgay K.

EMBO Mol Med. 2009 Apr;1(1):37-49. doi: 10.1002/emmm.200900002.

2.

Other inhibitors of viral enzymes and functions.

Zimmermann H, Hewlett G, Rübsamen-Waigmann H.

Handb Exp Pharmacol. 2009;(189):155-76. doi: 10.1007/978-3-540-79086-0_6. Review.

PMID:
19048200
3.

Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium.

Pohlscheidt M, Langer U, Minuth T, Bödeker B, Apeler H, Hörlein HD, Paulsen D, Rübsamen-Waigmann H, Henzler HJ, Reichl U.

Vaccine. 2008 Mar 17;26(12):1552-65. doi: 10.1016/j.vaccine.2008.01.032. Epub 2008 Feb 5.

PMID:
18295380
4.

Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.

Kaufman HE, Varnell ED, Gebhardt BM, Thompson HW, Atwal E, Rübsamen-Waigmann H, Kleymann G.

J Ocul Pharmacol Ther. 2008 Feb;24(1):34-42. doi: 10.1089/jop.2007.0084.

5.

Novel whole-cell antibiotic biosensors for compound discovery.

Urban A, Eckermann S, Fast B, Metzger S, Gehling M, Ziegelbauer K, Rübsamen-Waigmann H, Freiberg C.

Appl Environ Microbiol. 2007 Oct;73(20):6436-43. Epub 2007 Aug 24.

6.

Structure and total synthesis of lysobactin (katanosin B).

von Nussbaum F, Anlauf S, Benet-Buchholz J, Häbich D, Köbberling J, Musza L, Telser J, Rübsamen-Waigmann H, Brunner NA.

Angew Chem Int Ed Engl. 2007;46(12):2039-42. No abstract available.

PMID:
17211904
7.

Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages.

Bouazzaoui A, Kreutz M, Eisert V, Dinauer N, Heinzelmann A, Hallenberger S, Strayle J, Walker R, Rübsamen-Waigmann H, Andreesen R, von Briesen H.

Virology. 2006 Dec 5-20;356(1-2):79-94. Epub 2006 Aug 22.

8.

Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.

Kehlenbeck S, Betz U, Birkmann A, Fast B, Göller AH, Henninger K, Lowinger T, Marrero D, Paessens A, Paulsen D, Pevzner V, Schohe-Loop R, Tsujishita H, Welker R, Kreuter J, Rübsamen-Waigmann H, Dittmer F.

J Virol. 2006 Jul;80(14):6883-94.

9.

Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme.

Kuhl A, Svenstrup N, Ladel C, Otteneder M, Binas A, Schiffer G, Brands M, Lampe T, Ziegelbauer K, Rübsamen-Waigmann H, Haebich D, Ehlert K.

Antimicrob Agents Chemother. 2005 Mar;49(3):987-95.

10.

Antivirals against DNA viruses (hepatitis B and the herpes viruses).

Hewlett G, Hallenberger S, Rübsamen-Waigmann H.

Curr Opin Pharmacol. 2004 Oct;4(5):453-64. Review.

PMID:
15351349
11.

Human serum albumin-polyethylenimine nanoparticles for gene delivery.

Rhaese S, von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K.

J Control Release. 2003 Sep 19;92(1-2):199-208.

PMID:
14499197
12.

Human blood-derived macrophages enhance barrier function of cultured primary bovine and human brain capillary endothelial cells.

Zenker D, Begley D, Bratzke H, Rübsamen-Waigmann H, von Briesen H.

J Physiol. 2003 Sep 15;551(Pt 3):1023-32. Epub 2003 Jun 26.

13.

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.

Deres K, Schröder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Krämer T, Niewöhner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rübsamen-Waigmann H.

Science. 2003 Feb 7;299(5608):893-6.

14.

DNA from bovine papillomavirus type 2 induces warts in a xenograft model.

Pawellek A, Hewlett G, Rosenbruch M, Kreuter J, Rübsamen-Waigmann H.

Virus Res. 2002 Dec;90(1-2):365-70.

PMID:
12457989
15.

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

Betz UA, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H.

Antimicrob Agents Chemother. 2002 Jun;46(6):1766-72.

16.

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.

Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V, Baumeister J, Weber O, Henninger K, Keldenich J, Jensen A, Kolb J, Bach U, Popp A, Mäben J, Frappa I, Haebich D, Lockhoff O, Rübsamen-Waigmann H.

Nat Med. 2002 Apr;8(4):392-8.

PMID:
11927946
17.

Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors.

Eisert V, Kreutz M, Becker K, Königs C, Alex U, Rübsamen-Waigmann H, Andreesen R, von Briesen H.

Virology. 2001 Jul 20;286(1):31-44.

18.

Xenograft model for identifying chemotherapeutic agents against papillomaviruses.

Pawellek A, Hewlett G, Kreuter J, Rübsamen-Waigmann H, Weber O.

Antimicrob Agents Chemother. 2001 Apr;45(4):1014-21.

19.

Inhibition of HIV type 1 replication by simultaneous infection of peripheral blood lymphocytes with human immunodeficiency virus types 1 and 2.

Dern K, Rübsamen-Waigmann H, Unger RE.

AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):295-309.

PMID:
11242517
20.
22.
23.

A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models.

Weber O, Reefschläger J, Rübsamen-Waigmann H, Raddatz S, Hesseling M, Häbich D.

Antivir Chem Chemother. 2000 Jan;11(1):51-9.

PMID:
10693654
24.

Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.

Rübsamen-Waigmann H, Huguenel E, Shah A, Paessens A, Ruoff HJ, von Briesen H, Immelmann A, Dietrich U, Wainberg MA.

Antiviral Res. 1999 May;42(1):15-24.

PMID:
10333139
25.

Selection of HIV-1 genotypes by cultivation in different primary cells.

von Briesen H, Grez M, Ruppach H, Raudonat I, Unger RE, Becker K, Panhans B, Dietrich U, Rübsamen-Waigmann H.

AIDS. 1999 Feb 25;13(3):307-15.

PMID:
10199220
26.

Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli - two tags tie it up.

Maier G, Dietrich U, Panhans B, Schröder B, Rübsamen-Waigmann H, Cellai L, Hermann T, Heumann H.

Eur J Biochem. 1999 Apr;261(1):10-8.

27.

Restricted HIV type 1 replication under serum-free culture conditions in human monocyte-derived macrophages.

Kreutz M, Eisert V, Rübsamen-Waigmann H, Andreesen R, von Briesen H.

AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1581-8.

PMID:
9840291
28.

PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor.

Hock B, Böhme B, Karn T, Yamamoto T, Kaibuchi K, Holtrich U, Holland S, Pawson T, Rübsamen-Waigmann H, Strebhardt K.

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9779-84.

29.
30.
31.

Individual cell analysis of the cytokine repertoire in human immunodeficiency virus-1-infected monocytes/macrophages by a combination of immunocytochemistry and in situ hybridization.

Esser R, Glienke W, Andreesen R, Unger RE, Kreutz M, Rübsamen-Waigmann H, von Briesen H.

Blood. 1998 Jun 15;91(12):4752-60.

PMID:
9616174
32.

Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors.

Dietrich U, Ruppach H, Gehring S, Knechten H, Knickmann M, Jäger H, Wolf E, Husak R, Orfanos CE, Brede HD, Rübsamen-Waigmann H, von Briesen H.

AIDS. 1997 Oct;11(12):1532-3. No abstract available.

PMID:
9342084
33.

Molecular epidemiology of HIV in Israel.

Gehring S, Maayan S, Ruppach H, Balfe P, Juraszczyk J, Yust I, Vardinon N, Rimlawi A, Polak S, Bentwich Z, Rübsamen-Waigmann H, Dietrich U.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):296-303.

PMID:
9292589
34.

Expression of natural and synthetic genes encoding herpes simplex virus 1 protease in Escherichia coli and purification of the protein.

Apeler H, Gottschalk U, Guntermann D, Hansen J, Mässen J, Schmidt E, Schneider KH, Schneidereit M, Rübsamen-Waigmann H.

Eur J Biochem. 1997 Aug 1;247(3):890-5.

35.

Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load.

Rübsamen-Waigmann H, Huguenel E, Paessens A, Kleim JP, Wainberg MA, Shah A.

Lancet. 1997 May 24;349(9064):1517. No abstract available.

PMID:
9167463
36.
37.

Polo-like kinase, a novel marker for cellular proliferation.

Yuan J, Hörlin A, Hock B, Stutte HJ, Rübsamen-Waigmann H, Strebhardt K.

Am J Pathol. 1997 Apr;150(4):1165-72.

38.

[Serotypes of the human immunodeficiency virus type 1 in Madrid].

Soriano V, Dietrich U, Mas A, Andersen R, Bravo R, Ruppach H, Gutiérrez M, Martínez-Zapico R, Rübsamen-Waigmann H, González-Lahoz J.

Med Clin (Barc). 1997 Feb 15;108(6):217-20. Spanish.

PMID:
9102487
39.

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.

Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K.

Oncogene. 1997 Feb 6;14(5):543-9.

40.

Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus.

Esser R, Glienke W, von Briesen H, Rübsamen-Waigmann H, Andreesen R.

Blood. 1996 Nov 1;88(9):3474-81.

PMID:
8896413
41.

Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity.

Böhme B, VandenBos T, Cerretti DP, Park LS, Holtrich U, Rübsamen-Waigmann H, Strebhardt K.

J Biol Chem. 1996 Oct 4;271(40):24747-52.

42.

Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.

Bender AR, von Briesen H, Kreuter J, Duncan IB, Rübsamen-Waigmann H.

Antimicrob Agents Chemother. 1996 Jun;40(6):1467-71.

43.

Secondary structural elements as a basis for antibody recognition in the immunodominant region of human immunodeficiency viruses 1 and 2.

Markert RL, Ruppach H, Gehring S, Dietrich U, Mierke DF, Köck M, Rübsamen-Waigmann H, Griesinger C.

Eur J Biochem. 1996 Apr 1;237(1):188-204.

44.

Risk of HIV transmission in infected US military personnel.

Ruppach H, Knechten H, Jager H, Rubsamen-Waigmann H, Dietrich U.

Lancet. 1996 Mar 9;347(9002):697-8. No abstract available.

PMID:
8596420
45.

Circulating HIV-1 serotypes in Spain.

Soriano V, Andersen R, Mas A, Ruppach H, Bravo R, Gutiérrez M, Martinez-Zapico R, Rübsamen-Waigmann H, Dietrich U.

Vox Sang. 1996;70(4):236-7. No abstract available.

PMID:
9123932
46.

Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter.

Bräuninger A, Strebhardt K, Rübsamen-Waigmann H.

Oncogene. 1995 Nov 2;11(9):1793-800.

PMID:
7478607
47.

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.

Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Rösner M, Rübsamen-Waigmann H, Kaiser R, Wichers M, Schneweis KE, et al.

Antimicrob Agents Chemother. 1995 Oct;39(10):2253-7.

48.

The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials.

Kalish ML, Baldwin A, Raktham S, Wasi C, Luo CC, Schochetman G, Mastro TD, Young N, Vanichseni S, Rübsamen-Waigmann H, et al.

AIDS. 1995 Aug;9(8):851-7.

PMID:
7576318
49.

Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E.

Wasi C, Herring B, Raktham S, Vanichseni S, Mastro TD, Young NL, Rübsamen-Waigmann H, von Briesen H, Kalish ML, Luo CC, et al.

AIDS. 1995 Aug;9(8):843-9.

PMID:
7576317
50.

[Pyrido(3,2-e)(1,4)diazepines--synthesis and testing of anti-HIV-1 activity].

Görlitzer K, Wilpert C, Rübsamen-Waigmann H, Suhartono H, Wang L, Immelmann A.

Arch Pharm (Weinheim). 1995 Mar;328(3):247-55. German.

PMID:
7763140

Supplemental Content

Loading ...
Support Center